Figure 5.
(A) Schematic illustration of superstable homogeneous intermixed formulation technology (SHIFT) as a revolutionary strategy for transhepatic arterial chem otherapy and embolization (TACE). Reproduced with permission from 59, copyright 2020, Elsevier. (B) The clinic drugs and lipiodol are introduced to develop formulations with SHIFT at a controlled temperature and pressure overcoming current challenges in the liver cancer treatment with TACE. Reproduced with permission from 60, copyright 2022, Wiley.